There is always that Wall Street side looming in any company trading OTC and that's uplist. And if Cyrus Arman knows any investors all kinds of deals are possible that are about money and not the FDA/BP at least initially.

I think this share price is moving just because we have potential and are back in the game, puts the 350 m as more of investment.